Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

58.08 -1.65 (-2.77%)
Streaming Delayed Price Updated: 10:51 AM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
The Top 3 Biotech Stocks to Buy in March 2024
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors. 
Via InvestorPlace
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
The biotech company keeps moving closer to bringing its promising first gene therapy to market. 
Via The Motley Fool
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential. 
Via InvestorPlace
Topics Artificial Intelligence
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
 
Via Benzinga
Smart Money Is Betting Big In CRSP Options
 
Via Benzinga
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
This company's fortunes are likely to improve, and soon. 
Via The Motley Fool
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts. 
Via The Motley Fool
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
3 Biotech Stocks Bound to Blast Off By 2029
Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years. 
Via InvestorPlace
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
Check Out What Whales Are Doing With CRSP
 
Via Benzinga
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex shares have climbed almost 50% over the past year. 
Via The Motley Fool
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
Buy this stock if you're daring, but avoid it for now if you aren't. 
Via The Motley Fool
Three S&P 500 Giants Lead This List Of Stocks Near Buy Points
Watch these five stocks, but the market is slightly extended. 
Via Investor's Business Daily
Topics Stocks
Stock Market Rallies To Record High On Nvidia: Weekly Review
The stock market rally pulled back to start the week, but roared higher as booming Nvidia earnings and guidance fueled big AI-led gains. The S&P 500 and Dow Jones hit... Read More 
Via Investor's Business Daily
Topics Stocks
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Crispr Reports Its First Profit In 10 Quarters, And Shares Fly Out Of A Buy Zone
The company recently gained approval in the U.S. and abroad for its first gene-editing drug. 
Via Investor's Business Daily
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
These exciting players could deliver explosive growth over time. 
Via The Motley Fool
If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today
It would have been a great move. 
Via The Motley Fool
3 Stocks That Cathie Wood Is Loving Now: February 2024
Looking for high-growth opportunities? Here are three Cathie Wood stocks for long-term investors to consider now. 
Via InvestorPlace
What's Going On With Crispr Therapeutics Stock?
Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have... 
Via Benzinga
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. 
Via Benzinga
Topics Stocks
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.